Defining a minimal effective serum trough concentration of secukinumab in psoriasis: a step towards personalized therapy

The armamentarium of psoriasis treatments has been reinforced by the introduction of biologics that target interleukin-17A (IL-17A) (European Medicines Agency 2016; Frieder et al. 2018), and nowadays achieving complete skin clearance has become a realistic goal. However, in real life clinical practice, physicians encounter various levels of response, including insufficient response or loss of response upon anti-IL-17A treatment. This has led to physicians exploring off-label intensification regimens through trial-and-error, either by increasing the dose or by shortening the administration intervals (Beecker and Joo 2018; Phung et al.

Source: Journal of Investigative Dermatology - May 4, 2019 Category: Dermatology Authors: Rani Soenen, Evelyn Meulewaeter, Lynda Grine, Nathalie Van den Berghe, Els Brouwers, Reinhart Speeckaert, Sven Lanssens, Linda Temmerman, Jo Lambert, Ann Gils Tags: Letters to the Editor Source Type: research